Lataa...

Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab

The epidermal growth factor receptor (EGFR) is an ubiquitously expressed receptor tyrosine kinase (RTK) and is recognized as a key mediator of tumorigenesis in many human tumors. Currently there are five EGFR inhibitors used in oncology, two monoclonal antibodies (panitumumab and cetuximab) and thre...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Brand, Toni M, Dunn, Emily F, Iida, Mari, Myers, Rebecca A, Kostopoulos, Kellie T, Li, Chunrong, Peet, Chimera R, Wheeler, Deric L
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Landes Bioscience 2011
Aiheet:
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3219082/
https://ncbi.nlm.nih.gov/pubmed/21725209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4161/cbt.12.5.16394
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!